European Journal of Heart Failure

Article	Citations
Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes	1334
Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer	242
Morphine in acute pulmonary oedema: a signal of harm but more questions than answers	235
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme	205
May 2023 at a glance: focus on pathophysiology, comorbidities and devices	152
Issue Information	147
Letter regarding the article ‘Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure’	132
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	129
Issue Information	128
Alcohol consumption and incident heart failure in men and women	119
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials	115
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	114
Can we trust a smartwatch ECG? Potential and limitations	109
Current and novel biomarkers in cardiogenic shock	109
	107
Left atrial enlargement and biomarker profiles: Time for integration of biomarkers and echocardiography in heart failure prevention	99
Hypoalbuminaemia and heart failure: A practical review of current evidence	99
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	96
Global perspectives on heart failure with preserved ejection fraction: Unravelling regional variations in a complex syndrome	93
Differences in heart failure with preserved ejection fraction management between care providers: an international survey	89
Tailoring medical therapy for heart failure with preserved ejection fraction	88
Effects of atrial fibrillation ablation on arrhythmia burden and ventricular function in end‐stage heart failure: Lessons from CASTLE‐HTx	88
October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities	86
From prediction to prevention: The role of heart failure risk models	86
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	85

Time and left ventricular function: the forgotten dynamic factor	81
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials	80
What's all the fuss about a new guideline?	79
Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?	77
Heart failure: age is no excuse for complacency	76
Combination diuretic therapy for acute heart failure: ‘alone we can do so little; together we can do so much’	75
	75
Spironolactone, fibrosis and heart failure with preserved ejection fraction	71
September 2022 at a glance	67
Plasma markers to risk stratify for heart failure in atrial fibrillation	62
Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart	61
Early changes in renal function after sodium–glucose cotransporter 2 inhibitor initiation in EMPEROR‐Reduced: the end of the dilemma?	59
Issue Information	58
Cause‐specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry	57
Reply to ‘Digoxin and beta‐blockers in patients with heart failure’. Letter regarding the article ‘Clinical outcomes with digoxin vs. beta‐blocker for heart rate control in permanent atrial fibrillati	56
Issue Information	55
Quality over quantity: Assessing the need for multiple biomarkers in predicting heart failure outcomes	55
Moving forwards from clinical trials to a more individualized management of treatments in heart failure? Great value of Doppler echocardiography data	54
Optimizing heart rate with ivabradine in heart failure with reduced ejection fraction: Insights from a post‐hoc analysis of the SHIFT trial	54
The frail patient and the frailing heart. Letter regarding the article ‘Barcelona Bio‐HF calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor	53
Exercise left atrial compliance: One more tool in the heart failure with preserved ejection fraction assistance toolbox?	53
Change in ejection fraction and long‐term mortality in adults referred for echocardiography	53
N‐terminal pro‐B‐type natriuretic peptide post‐discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study	52
Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial	52
Reply to ‘Vericiguat in heart failure with reduced ejection fraction: the right choice above all else? The answermay lie in time’	52
Issue Information	51
Can biomarkers help find the ‘sweet spot’ for treating patients with diabetes?	51
Letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’	51
Cardiac immune‐related adverse events: an immune‐cardio‐oncology puzzle	50
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial	50
Provocative testing in the evaluation of heart failure with preserved ejection fraction: Not all stresses are created equal	50
Issue Information	50
Left atrial volume index and outcome after transcatheter edge‐to‐edge valve repair for secondary mitral regurgitation	49
The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: a call to action for detecting atrial fibrillation and improving outcome	48
Methodological and reporting issues for meta‐analysis of immune checkpoint inhibitor‐associated cardiotoxicity. Letter regarding the article ‘Cardiotoxicity associated with immune checkpoint inhibitor	47
Issue Information	47
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	47
Personalizing anti‐inflammatory therapy in heart failure: A new way	46
Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial	46
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	46
Oral sucrosomial iron in heart failure with a reduced ejection fraction	45
Sex and central obesity in heart failure with preserved ejection fraction	45
Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percut	45
Exercise‐induced changes in pulmonary artery wedge pressure in adults post‐Fontan versus heart failure with preserved ejection fraction and non‐cardiac dyspnoea	45
Optimizing evidence‐based heart failure medication: every contact counts	44
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices	44
July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy	44
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy‐associated genes: A subgroup analysis of the PARADIGM‐HF trial	43
June 2023 at a glance: focus on worsening heart failure, heart failure with preserved ejection fraction and valvular heart disease	43
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone	43

The left atrium in cardiac amyloidosis: a valuable but still underused observation window on the overall disease process	43
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	43
Transcatheter mitral valve repair for primary and secondary mitral regurgitation: new insights from a nationwide registry	43
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial	42
	42
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	42
Heart failure with preserved ejection fraction and COVID‐19: which comes first, the chicken or the egg? Letter regarding the article ‘Heart failure with preserved ejection fraction accordin	41
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure?	41
Detecting subclinical congestion in stage A/B pre‐heart failure: a glimpse into the future?	41
Issue Information	41
Reply to ‘Phenotypic characterization of heart failure with preserved ejection fraction’	41
Obituary: Paulo Bettencourt 1965–2021	40
October 2022 at a glance: focus on clinical trials	40
Letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized	39
Reply to ‘Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease’	39
Dapagliflozin effect on heart failure with prevalent or new‐onset atrial fibrillation	39
Issue Information	39
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices	39
Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI	38
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	38
Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study	38
Issue Information	37
Eligibility for vericiguat in a real‐world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry	37
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	37
Clinical characteristics and prognosis of patients with isolated cardiac sarcoidosis: Insights from the ILLUMINATE‐CS study	37
Pathophysiology of Takotsubo syndrome: still a puzzle. Letter regarding the article ‘Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo S	37
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF	36
Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1‐year results	36
Classifying heart failure based on ejection fraction: imperfect but enduring	36
Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atria	35
Peripartum cardiomyopathy and pre‐eclampsia: two tips of the same iceberg	34
The heart of dystrophinopathies	34
Growth differentiation factor‐15 in sodium–glucose cotransporter 2 inhibition: Mechanistic insights from the EMPEROR program	34
New cimlanod trial provides insights into mechanistic effects of vasodilators in heart failure	34
Diagnostic models to differentiate Takotsubo syndrome from acute coronary syndrome: A systematic review and meta‐analysis	34
Issue Information	34
Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia‐ exposed human cardiomyocytes through comprehensive multi‐level analysis	34
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	33
Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial	33
Phenotype, outcomes and natural history of early‐stage non‐ischaemic cardiomyopathy	33
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	33
Tricuspid regurgitation risk scores in patients undergoing tricuspid valve transcatheter edge‐to‐edge repair	33
Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis?	33
Timing of veno‐arterial extracorporeal membrane oxygenation support in patients with cardiogenic shock	33
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	33
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis	32
Natriuretic peptides – Biomarker companions through thick and thin	32
Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark. Letter regarding the article ‘Improved long‐term survival with tafamidis treatment in patients with transt	32
Acute lower‐limb heating improves exercise performance in individuals with heart failure with reduced ejection fraction	31
Improving renal function during diuresis: useful information or just noise?	31
Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC,	31
Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: Results from the open‐label extension of the PARADIGM‐HF study	31
Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab	31
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	30
Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	30
Issue Information	30
The small molecule ACM‐001 improves cardiac function in a rat model of severe cancer cachexia	30
Targeting the nitrate–nitrite–nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?	30
Reply to ‘Sex hormones and heart failure’	29
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	29
Letter regarding the article ‘Changes in 6‐min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction’	29
Pulmonary congestion in patients with pulmonary arterial hypertension? New insights from lung ultrasound	29
Dissecting the heart failure phenotype through phenomics	29
	29
Issue Information	29
Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron‐deficient heart failure	29
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncol	28
Transcatheter aortic valve replacement in heart failure	28
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	28
The transcriptional profile of iron deficiency in patients with heart failure: Heme‐sparing and reduced immune processes	28
Trajectories of renal biomarkers and new‐onset heart failure in the general population: Findings from the PREVEND study	28
Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good	28
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	28
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial	28
Assessing the association between genetic and phenotypic features of dilated cardiomyopathy and outcome in patients with coronary artery disease	28
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	28
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro	27
Mitral regurgitation and heart failure with preserved ejection fraction: Should we treat the muscle, the valve, or both?	27
Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’	27
Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?	27

Impact of guideline‐directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta‐analysis	27
What about current recommendations for extracorporeal life support in acute myocardial infarction‐associated cardiogenic shock: Stay or go? or time to revise?	27
Reply to ‘Breaking down peripartum cardiomyopathy: A learning adventure’	27
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics	26
Cardioprotective effects of semaglutide on isolated human ventricular myocardium	26
Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF‐VAD registry	26
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES	26
Deep phenotyping of p.(V142I)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis?	25
Influence of temperature on haemodynamic changes in heart failure: A CardioMEMS pulmonary artery monitoring analysis	25
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	25
Unravelling the complexity of heart failure with preserved ejection fraction and secondary mitral regurgitation	25
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	25
Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta‐analysis	25
Towards more practical phenotyping in heart failure with preserved ejection fraction	25
Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS st	25
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	25
Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives	25
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	25
Worsening renal function precedes and follows worsening heart failure	25
Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study	25
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure	25
Letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	25
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial	24
Reply to the letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND	24
The strategic vision of the 2022–2024 mandate – greater involvement of members, young specialists for an HFA community without borders	24
Corrigendum to ‘The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study’ [Eur J Heart Fail 2022;24	24
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	24
Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey	24
Striving for the ‘perfect’ definition of iron deficiency in heart failure	24
Corrigendum to ‘High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality’ [Eur J Heart Fail 2021;23:919–932]	24
Corrigendum to ‘Weight change and clinical outcomes in heart failure with reduced ejection fraction: Insights from EMPEROR‐Reduced’ [Eur J Heart Fail 2023;25:117–127]	24
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study	24
Sexual dimorphism in the relationships between intramyocardial fat, myocardial fibrosis, and exercise intolerance in heart failure with preserved ejection fraction	24
Implementation of sodium–glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be	24
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	24
Corrigendum to ‘Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials’ [Eur J	24
Corrigendum to ‘Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction’ [Eur J Heart Fail 2022;24:782–790]	24
Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction	23
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial	23
Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology	23
Knowledge and application of ESC/HFA guidelines in the management of advanced heart failure	23
Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population	23
Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis	23
Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling	23
Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study	22
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map	22
European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC	22
BLITZ‐HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines	22
Is palliative care in heart failure patients coming up?	22
Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study	22
	22
Association between secondhand smoke exposure and incident heart failure: The Multi‐Ethnic Study of Atherosclerosis (MESA)	22
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	21
Rationale and design of the FAIR‐HF2‐DZHK05 trial: Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failu	21
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study	21
Clinical effect of obesity on N‐terminal pro‐B‐type natriuretic peptide cut‐off concentrations for the diagnosis of acute heart failure	21
Supervised exercise training in patients with advanced heart failure and left ventricular assist device: A multicentre randomized controlled trial (Ex‐VAD trial)	21
Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC	21
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	21
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis	21
Practical outpatient management of worsening chronic heart failure	21
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje	21
Interatrial shunting for the treatment of heart failure: an on‐demand, self‐regulating left atrial pressure lowering system	20
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	20
Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial	20
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety	20
Potential global impact of sodium–glucose cotransporter‐2 inhibitors in heart failure	20
Abstract	20
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey	19
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER	19
Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)	19
Evolution of tricuspid regurgitation after transcatheter edge‐to‐edge mitral valve repair for secondary mitral regurgitation and its impact on mortality	19
Targeting the ‘vulnerable’ period – first 3–6 months after an acute heart failure admission – the light gets brighter	19
December 2023 at a glance: Focus on medical therapy in chronic and acute heart failure	19
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial	19
Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry	19
Impact of the COVID‐19 pandemic on prescription of sacubitril/valsartan in Italy	19
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care	19
Diagnostic value of reduced left atrial compliance during ergometry exercise in heart failure with preserved ejection fraction	19
Effect of patisiran on stroke volume in hereditary transthyretin‐mediated amyloidosis: insights from pressure–volume analysis of the APOLLO study	19
Pulmonary hypertension across the spectrum of left heart and lung disease	18
Applicability of heart failure clinical practice guidelines in low‐ and middle‐income countries	18
	18
Issue Information	18
Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The RevascHeart study	18
Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study	18
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology	18
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial	18
Barriers to the implementation of heart failure therapy in the elderly: Let's accept the challenge!	18
Beyond loop diuretics: Unlocking the potential of co‐diuretics in heart failure management	17
Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States	17
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF	17
Implementation of guideline‐directed medical therapy for heart failure	17
Observational study for multiparametric assessment of cardiac congestion in outpatient worsening heart failure (EVOLUTION)	17
Serial direct sodium removal in patients with heart failure and diuretic resistance	17